NHS England » NHS to roll out long-lasting ‘suit of armour’ jab to protect thousands of premature babies from RSV ...

Despite strong clinical data, RSV immunization rates among pregnant women and older adults remain worryingly low, ...

The risk for severe RSV-related outcomes was effectively reduced among children and infants who received nirsevimab in real-world clinical settings.

Vulnerable premature babies who need extra protection against RSV may receive six months’ protection in a long-lasting single ...

A new antibody shot that protects babies against RSV infection could be struggling to gain traction, Philadelphia researchers ...

John Stewart, Director of Specialised Commissioning at NHS England said: “For babies born very prematurely, the risk of ...

Despite adequate availability of nirsevimab, only about one third of eligible children receive it for respiratory syncytial virus prophylaxis, with uptake varying by race and other social factors.

Despite near universal availability of nirsevimab, only 35% of eligible children receive nirsevimab for RSV prophylaxis.

Respiratory Syncytial Virus (RSV) is the leading cause of hospitalization in all infants. 1-5 Nirsevimab is being investigated as a first-in-class single dose immunization to provide protection ...

Nirsevimab, a monoclonal antibody recently approved to prevent respiratory syncytial virus-associated lower respiratory disease in newborns and infants, may protect longer than an RSV season ...

New nirsevimab data analyses reinforce efficacy against RSV. A prespecified pooled analysis of Phase 3 and Phase 2b data demonstrated an efficacy of 79.5% against medically attended lower respiratory ...

Nirsevimab demonstrated protectionagainst respiratory syncytial virus diseasein healthy infants in Phase 3 trial PARIS– April 26, 2021 – Positive topline results from the Phase 3 MELODY trial ...